Review
The changing role of the pathologist in the management of Barrett's oesophagus
Suzanne A Hopcroft,
Neil A Shepherd,
Suzanne A Hopcroft
Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK
Search for more papers by this authorCorresponding Author
Neil A Shepherd
Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK
Addressee for correspondence: Professor N A Shepherd, Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Sandford Road, Cheltenham, GL53 7AN, UK. e-mail: [email protected]Search for more papers by this authorSuzanne A Hopcroft,
Neil A Shepherd,
Suzanne A Hopcroft
Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK
Search for more papers by this authorCorresponding Author
Neil A Shepherd
Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK
Addressee for correspondence: Professor N A Shepherd, Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Sandford Road, Cheltenham, GL53 7AN, UK. e-mail: [email protected]Search for more papers by this authorS.A.H. and N.A.S. contributed equally to this work.
Abstract
Pathological specimens from columnar-lined oesophagus (CLO) comprise a considerable proportion of the workload of gastrointestinal pathologists in Western countries. There remain controversies concerning the diagnostic role of pathology. More recently, in the UK at least, the diagnosis has been regarded as primarily an endoscopic endeavour, with pathology being corroborative and only diagnostic when endoscopic features are equivocal or when there are additional features that make the endoscopic diagnosis unclear. There is also recognition that demonstration of intestinalisation or ‘goblet cells’ is not paramount, and should not be required for the diagnosis. There have been notable changes in the management of CLO neoplasia: pathologists are centrally involved in its management. Pathological assessment of endoscopic mucosal resection (EMR) specimens provides the most useful means of determining the management of early neoplasia and of determining indications for surgery. This represents an extraordinarily rapid change in management, in that, <10 years ago, laborious Seattle-type biopsy protocols were recommended, and high grade dysplasia was an indication for resectional surgery. Now, individual patient management is paramount: multi-professional meetings determine management after biopsy and EMR assessment. One significant change is that major resections are undertaken less often, in Western countries, for CLO neoplasia.
References
- 1Barrett NR. Chronic peptic ulcer of the oesophagus and oesophagitis. Br. J. Surg. 1950; 38; 175–182.
- 2Spechler SJ. The columnar-lined esophagus. History, terminology, and clinical issues. Gastroenterol. Clin. North Am. 1997; 26; 455–466.
- 3Williamson JM, Almond LM, Shepherd NA et al. Current management of Barrett's oesophagus. Br. J. Hosp. Med. (Lond). 2012; 73; 271–277.
- 4Prach AT, MacDonald TA, Hopwood DA et al. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 1997; 350; 933.
- 5van Soest EM, Dieleman JP, Siersema PD et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54; 1062–1066.
- 6Winters C Jr, Spurling TJ, Chobanian SJ et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92; 118–124.
- 7Eisen GM, Sandler RS, Murray S et al. The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. Am. J. Gastroenterol. 1997; 92; 27–31.
- 8Csendes A, Smok G, Burdiles P et al. Prevalence of Barrett's esophagus by endoscopy and histologic studies: a prospective evaluation of 306 control subjects and 376 patients with symptoms of gastroesophageal reflux. Dis. Esophagus 2000; 13; 5–11.
- 9Singh P, Taylor RH, Colin-Jones DG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am. J. Gastroenterol. 1994; 89; 349–356.
- 10Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am. J. Gastroenterol. 1997; 92; 1293–1297.
- 11Corley DA, Kubo A, Levin TR et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006. Gut 2009; 58; 182–188.
- 12Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J. Clin. Gastroenterol. 2001; 33; 306–309.
- 13Edelstein ZR, Farrow DC, Bronner MP et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007; 133; 403–411.
- 14El-Serag HB, Kvapil P, Hacken-Bitar J et al. Abdominal obesity and the risk of Barrett's esophagus. Am. J. Gastroenterol. 2005; 100; 2151–2156.
- 15Cook MB, Shaheen NJ, Anderson LA et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012; 142; 744–753.
- 16Kubo A, Levin TR, Block G et al. Cigarette smoking and the risk of Barrett's esophagus. Cancer Causes Control 2009; 20; 303–311.
- 17Anderson LA, Cantwell MM, Watson RGP et al. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009; 136; 799–805.
- 18Thrift AP, Pandeya N, Smith KJ et al. Lifetime alcohol consumption and risk of Barrett's Esophagus. Am. J. Gastroenterol. 2011; 106; 1220–1230.
- 19Yousef F, Cardwell C, Cantwell MM et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am. J. Epidemiol. 2008; 168; 237–249.
- 20Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 2011; 365; 1375–1383.
- 21 Cancer Research UK. Oesophageal cancer – UK incidence and statistics. Available at: http://info.cancerresearchuk.org/cancerstats/types/oesophagus/incidence/uk-oesophageal-cancer-incidence-statistics (last accessed 08.05.2013).
- 22Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br. J. Cancer 1990; 62; 440–443.
- 23Watson A. Barrett's oesophagus - 50 years on. Br. J. Surg. 2000; 87; 529–531.
- 24Menke-Pluymers MBE, Hop WCJ, Dees J et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. Cancer 1993; 72; 1155–1158.
10.1002/1097-0142(19930815)72:4<1155::AID-CNCR2820720404>3.0.CO;2-C PubMed Web of Science® Google Scholar
- 25Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131; 1392–1399.
- 26Takubo K, Vieth M, Aida J et al. Differences in the definitions used for esophageal and gastric diseases in different countries. Endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion 2009; 80; 248–257.
- 27Aida J, Vieth M, Ell C et al. Palisade vessels as a new histologic marker of esophageal origin in ER specimens from columnar-lined esophagus. Am. J. Surg. Pathol. 2011; 35; 1140–1145.
- 28Weston AP, Krmpotich P, Makdisi WF et al. Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Am. J. Gastroenterol. 1996; 91; 981–986.
- 29Goldblum JR. Ultrashort-segment Barrett's oesophagus, carditis and intestinal metaplasia at the oesophagogastric junction: pathology, causation and implications. Curr. Diagn. Pathol. 2003; 9; 228–234.
10.1016/S0968-6053(03)00032-2 Google Scholar
- 30Hackelsberger A, Gunther T, Schultze V et al. Intestinal metaplasia at the gastroesophageal junction: Helicobacter pylori gastritis or gastro-esophageal reflux disease? Gut 1998; 43; 17–21.
- 31Goldblum JR, Richter JE, Vaezi M et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am. J. Gastroenterol. 2002; 97; 302–311.
- 32Morales TG, Camargo E, Bhattacharyya A et al. Long-term follow-up of intestinal metaplasia of the gastric cardia. Am. J. Gastroenterol. 2000; 95; 1677–1680.
- 33Watson A, Heading RC, Shepherd NA et al. Guidelines for the diagnosis and management of Barrett's columnar lined oesophagus. A report of the working party of the British Society of Gastroenterology, 2005. Available at: http://www.bsg.org.uk (accessed 25/02/2013).
- 34Levine DS, Haggitt RC, Blount PL et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993; 105; 40–50.
- 35Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol. Clin. North Am. 1997; 26; 613–634.
- 36Curvers WL, Singh R, Song LM et al. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus: a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 2008; 57; 167–172.
- 37Herrero LA, Curvers WL, Bansal A et al. Zooming in on Barrett oesophagus using narrow-band imaging: an international observer agreement study. Eur. J. Gastroenterol. Hepatol. 2009; 21; 1068–1075.
- 38Pohl J, Pech O, May A et al. Incidence of macroscopically occult neoplasias in Barrett's esophagus: are random biopsies dispensable in the era of advanced endoscopic imaging? Am. J. Gastroenterol. 2010; 105; 2350–2356.
- 39Harrison R, Perry I, Haddadin W et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007; 102; 1154–1161.
- 40Attwood SE, Morris CD. Who defines Barrett's oesophagus: endoscopist or pathologist? Eur. J. Gastroenterol. Hepatol. 2001; 13; 97–99.
- 41Takubo K, Nixon JM, Jass JR. Ducts of esophageal glands proper and Paneth cells in Barrett's esophagus: frequency in biopsy specimens. Pathology 1995; 27; 315–317.
- 42Coad RA, Woodman AC, Warner PJ et al. On the histogenesis of Barrett's oesophagus and its associated squamous islands: a three-dimensional study of their morphological relationship with native oesophageal gland ducts. J. Pathol. 2005; 206; 388–394.
- 43Shields HM, Rosenberg SJ, Zwas FR et al. Prospective evaluation of multilayered epithelium in Barrett's esophagus. Am. J. Gastroenterol. 2001; 96; 3268–3273.
- 44Glickman JN, Spechler SJ, Souza RF et al. Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am. J. Surg. Pathol. 2009; 33; 818–825.
- 45Glickman JN, Chen YY, Wang HH et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's esophagus. Am. J. Surg. Pathol. 2001; 25; 569–578.
- 46Srivastava A, Odze RD, Lauwers GY et al. Morphologic features are useful in distinguishing Barrett esophagus from carditis with intestinal metaplasia. Am. J. Surg. Pathol. 2007; 31; 1733–1741.
- 47Shi L, Der R, Ma Y et al. Gland ducts and multilayered epithelium in mucosal biopsies from gastroesophageal-junction region are useful in characterizing esophageal location. Dis. Esophagus 2005; 18; 87–92.
- 48Takubo K, Aida J, Sawabe M et al. The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endoscopy. Best Pract. Res. Clin. Gastroenterol. 2008; 22; 569–583.
- 49Lavery D, Nicholson A, Poulsom R et al. The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands. Gut 2014; published on line ahead of print at Gut doi:10.1136/gutjnl-2013-306508.
- 50Krishnamurthy S, Dayal Y. Pancreatic metaplasia in Barrett's esophagus. An immunohistochemical study. Am. J. Surg. Pathol. 1995; 19; 1172–1180.
- 51Spechler SJ, Sharma P, Souza RF et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140; e18–e52.
- 52Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink - is intestinal metaplasia dead? Am. J. Gastroenterol. 2009; 104; 2588–2594.
- 53Wang H, Brown I, Kumarasinghe P et al. Poor agreement for detection of goblet cells in esophageal and GEJ biopsies. Lab. Invest. 2012; 92; 152–188.
- 54Csendes A, Smok G, Burdiles P et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis. Esophagus 2003; 16; 24–28.
- 55Gatenby PA, Ramus JR, Caygill CP et al. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand. J. Gastroenterol. 2008; 43; 524–530.
- 56Chandrasoma PT, Der R, Dalton P et al. Distribution and significance of epithelial types in columnar-lined esophagus. Am. J. Surg. Pathol. 2001; 25; 1188–1193.
- 57Chandrasoma P, Wijetunge S, DeMeester S et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am. J. Surg. Pathol. 2012; 36; 1–7.
- 58Kelty CJ, Gough MD, van Wyk Q et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007; 42; 1271–1274.
- 59Liu W, Hahn H, Odze RD et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell containing epithelium. Am. J. Gastroenterol. 2009; 104; 816–824.
- 60Hahn HP, Blount PL, Ayub K et al. Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus. Am. J. Surg. Pathol. 2009; 33; 1006–1015.
- 61Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod. Pathol. 2004; 17; 1282–1288.
- 62Takubo K, Aida J, Naomoto Y et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum. Pathol. 2009; 40; 65–74.
- 63Golden K, Srivastava A, Sanchez CA et al. High goblet cell density protects against progression to adenocarcinoma in patients with Barrett's esophagus. Mod. Pathol. 2011; 24; 149A.
- 64Tang P, McKinley MJ, Sporrer M et al. Inlet patch: prevalence, histologic type, and association with esophagitis, Barrett esophagus, and antritis. Arch. Pathol. Lab. Med. 2004; 128; 444–447.
- 65Shepherd NA. Barrett's oesophagus. In NA Shepherd, BF Warren, GT Williams, JK Greenson, GY Lauwers, MR Novelli, eds. Morson & Dawson's gastrointestinal pathology. 5th ed. Oxford: John Wiley, 2013; 39–51.
10.1002/9781118399668 Google Scholar
- 66Fitzgerald RC, di Pietro M, Ragunath K et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Available at: http://www.bsg.org.uk/clinical-guidelines/oesophageal/guidelines-on-the-diagnosis-and-management-of-barrett-s-oesophagus.html. Accessed on 25.11.13.
- 67Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983; 14; 931–968.
- 68Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47; 251–255.
- 69Kerkhof M, van Dekken H, Steyerberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50; 920–927.
- 70Lomo LC, Blount PL, Sanchez CA et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort. Am. J. Surg. Pathol. 2006; 30; 423–435.
- 71Coco DP, Goldblum JR, Hornick JL et al. Interobserver variability in the diagnosis of crypt dysplasia in Barrett esophagus. Am. J. Surg. Pathol. 2011; 35; 45–54.
- 72Zhang X, Huang Q, Goyal R et al. High fidelity image cytometry in neoplastic lesions in Barrett's esophagus, including basal crypt dysplasia-like atypia with surface maturation. Lab. Invest. 2007; 87; 133A.
- 73Rucker-Schmidt RL, Sanchez CA, Blount PL et al. Nonadenomatous dysplasia in Barrett esophagus: a clinical, pathologic, and DNA content flow cytometric study. Am. J. Surg. Pathol. 2009; 33; 886–893.
- 74Mahajan D, Bennett AE, Liu X et al. Grading of gastric foveolar-type dysplasia in Barrett's esophagus. Mod. Pathol. 2010; 23; 1–11.
- 75Odze RD. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr. Opin. Gastroenterol. 2011; 27; 389–396.
- 76Srivastava A, Sanchez CA, Cowan DS et al. Foveolar and serrated dysplasia are rare high-risk lesions in Barrett's esophagus: a prospective outcome analysis of 214 patients. Mod. Pathol. 2010; 23; 742A.
- 77Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010; 105; 1523–1530.
- 78Reid BJ, Haggitt RC, Rubin CE et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 1988; 19; 166–178.
- 79Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am. J. Gastroenterol. 2000; 95; 3383–3387.
- 80Srivastava A, Hornick JL, Li X et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am. J. Gastroenterol. 2007; 102; 483–493.
- 81Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum. Pathol. 2001; 32; 379–388.
- 82Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum. Pathol. 2001; 32; 368–378.
- 83Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J. Clin. Pathol. 2006; 59; 1029–1038.
- 84Buttar NS, Wang KK, Sebo TJ et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120; 1630–1639.
- 85Zhu W, Appelman HD, Greenson JK et al. A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am. J. Clin. Pathol. 2009; 132; 94–100.
- 86Montgomery E, Bronner MP, Greenson JK et al. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up. Am. J. Gastroenterol. 2002; 97; 27–31.
- 87Abraham SC, Wang H, Wang KK et al. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma. Am. J. Surg. Pathol. 2008; 32; 1068–1074.
- 88Thurberg BL, Duray PH, Odze RD. Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases. Hum. Pathol. 1999; 30; 745–752.
- 89Paraf F, Fléjou JF, Potet F et al. Adenomas arising in Barrett's esophagus with adenocarcinoma. Report of three cases. Pathol. Res. Pract. 1992; 188; 1028–1032.
- 90Wong RS, Temes RT, Follis FM et al. Multiple polyposis and adenocarcinoma arising in Barrett's esophagus. Ann. Thorac. Surg. 1996; 61; 216–218.
- 91Ormsby AH, Petras RE, Henricks WH et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut 2002; 51; 671–676.
- 92Downs-Kelly E, Mendelin JE, Bennett AE et al. Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pre-treatment Barrett's esophagus biopsies. Am. J. Gastroenterol. 2008; 103; 2333–2340.
- 93Maish MS, DeMeester SR. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma. Ann. Thorac. Surg. 2004; 78; 1777–1782.
- 94Bergman JJ. Diagnosis and therapy of early neoplasia in Barrett's esophagus. Curr. Opin. Gastroenterol. 2005; 21; 466–471.
- 95Pouw RE, Bergman JJ. Endoscopic resection of early oesophageal and gastric neoplasia. Best Pract. Res. Clin. Gastroenterol. 2008; 22; 929–943.
- 96Alderson D. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma: another spanner in the works? Gut 2002; 51; 620–621.
- 97Rubio CA, Riddell R. Musculo-fibrous anomaly in Barrett's mucosa with dysplasia. Am. J. Surg. Pathol. 1988; 12; 885–889.
- 98Takubo K, Sasajima K, Yamashita K et al. Double muscularis mucosae in Barrett's esophagus. Hum. Pathol. 1991; 22; 1158–1161.
- 99Lewis JT, Wang KK, Abraham SC. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for Barrett esophagus: implications for staging of adenocarcinoma. Am. J. Surg. Pathol. 2008; 32; 566–571.
- 100Abraham SC, Krasinskas AM, Correa AM et al. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. Am. J. Surg. Pathol. 2007; 31; 1719–1725.
- 101Kaneshiro DK, Post JC, Rybicki L et al. Clinical significance of the duplicated muscularis mucosae in Barrett esophagus-related superficial adenocarcinoma. Am. J. Surg. Pathol. 2011; 35; 697–700.
- 102Biddlestone LR, Barham CR, Wilkinson SP et al. The histopathology of treated Barrett's esophagus: squamous reepithelialization after acid suppression and laser and photodynamic therapy. Am. J. Surg. Pathol. 1998; 22; 239–245.
- 103Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am. J. Gastroenterol. 2011; 106; 1899–1908.
Citing Literature
